cyclopentane has been researched along with azacitidine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Advani, AS; Beausoleil, SA; Carew, JS; Carraway, HE; Espitia, CM; Han, Y; Kelly, KR; Maciejewski, JP; Nawrocki, ST; Nazha, A; Possemato, A; Sekeres, MA; Visconte, V | 1 |
| Fathi, AT | 1 |
| Adès, L; Bell, J; Campelo, MD; Cerrano, M; Faller, DV; Fram, RJ; Friedlander, S; Graux, C; Liesveld, J; Lopez, PF; Radinoff, A; Sangerman, MA; Sekeres, MA; Selleslag, D; Tzvetkov, N; Watts, J; Zeidner, JF; Zhao, D | 1 |
| Bowen, S; Dai, Y; Faller, DV; Friedlander, S; Haikawa, K; Hua, Z; Kupperman, E; Kuroda, S; Nakai, K; Sedarati, F; Venkatakrishnan, K; Yamamoto, Y; Yuan, Y; Zhou, X | 1 |
| Arrate, MP; Boghaert, ER; Cojocari, D; Gorska, A; Hogdal, LJ; Huska, JD; Phillips, DC; Purkal, JJ; Ramsey, HE; Savona, MR; Smith, BN; Xiao, Y | 1 |
| Agelopoulos, K; Berdel, WE; Göllner, S; Klosner, J; Müller-Tidow, C; Rohde, C; Schliemann, C | 1 |
| Adès, L; Anagnostopoulos, A; De Paz Arias, R; Díez-Campelo, M; Doronin, VA; Faller, DV; Fram, RJ; Friedlander, S; Girshova, L; Kambhampati, S; Munhoz, EC; Platzbecker, U; Santini, V; Sekeres, MA; Symeonidis, A; Valcárcel, D; Viniou, NA; Woszczyk, D; Yuan, Y | 1 |
| Arellano, ML; Baer, MR; Ball, BJ; Blum, W; Borate, U; Boyiadzis, MM; Burd, A; Byrd, JC; Chen, T; Collins, RH; Deininger, M; Druker, BJ; Duong, VH; Foran, JM; Foster, MC; Gana, TJ; Heerema, NA; Kaufmann, SH; Kovacsovics, T; Levine, RL; Lin, TL; Litzow, MR; Marcus, S; Martycz, M; Mims, AS; Odenike, O; Olin, RL; Patel, PA; Peterson, KL; Rosenberg, L; Saliba, AN; Schiller, GJ; Schneider, PA; Shoben, AB; Stefanos, M; Stein, EM; Stock, W; Traer, E; Walker, A; Yocum, AO | 1 |
4 trial(s) available for cyclopentane and azacitidine
| Article | Year |
|---|---|
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Pyrimidines | 2021 |
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Azacitidine; Cyclopentanes; Drugs, Investigational; Global Burden of Disease; Humans; Incidence; International Cooperation; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Myelodysplastic Syndromes; Pharmacology, Clinical; Pyrimidines; Translational Research, Biomedical; Ubiquitin-Activating Enzymes; United States | 2021 |
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Drug Therapy, Combination; Humans; Leukemia, Myelomonocytic, Chronic; Pyrimidines | 2022 |
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Topics: Aged; Azacitidine; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Pyrimidines; Tumor Suppressor Protein p53 | 2023 |
4 other study(ies) available for cyclopentane and azacitidine
| Article | Year |
|---|---|
Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.
Topics: Azacitidine; Cell Line, Tumor; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Neoplasm Proteins; Proteomics; Pyrimidines | 2016 |
Pevonedistat, a new partner for 5-azacitidine.
Topics: Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; NEDD8 Protein; Pyrimidines | 2018 |
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Pyrimidines; Sulfonamides | 2022 |
Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia.
Topics: Azacitidine; Chemokine CXCL12; Combined Modality Therapy; Cyclopentanes; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; NEDD8 Protein; Pre-B-Cell Leukemia Transcription Factor 1; Pyrimidines; RNA Interference; Signal Transduction | 2021 |